Anti-nuclear Antibody (ANA) Testing Market 2019 by type (immunofluorescence, enzymelinked, immunosorbent assay (ELISA) and others), by application (Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Polymyositis, Scleroderma, Sjögren’s syndrome, and others), by End User (Hospitals and clinics, research laboratories, and others) – Forecast to 2023
Market Synopsis:
Anti-nuclear antibody (ANA) test is generally performed to detect the presence of antinuclear antibodies in the blood. Anti-nuclear antibodies are referred to as autoantibodies which get attached to specific content of the nucleus of the cell. Also termed as an antinuclear factor, autoantibodies are produced in the human body in order to fight against the foreign particles. The most common ANA tests include enzyme-linked immunosorbent assay and indirect immunofluorescence test.
“Global Anti-Nuclear Antibody (ANA) testing market is expected to strike a robust CAGR of 9.6% during the forecast period. The valuation of the market is set to reach USD 1300.6 Mn by the end of 3023”.
Free Sample Copy at https://www.marketresearchfuture.com/sample_request/3210
The rising healthcare expenditure coupled with increasing awareness about autoimmune diseases is projected to propel the expansion of the Anti-Nuclear Antibody (ANA) testing market over the next couple of years.
Furthermore, the availability of funds for research & development as well as firm support extended by the governments is poised to boost the proliferation of the Anti-Nuclear Antibody (ANA) testing market through the assessment period.
Market Segmentation:
By type, the global Anti-Nuclear Antibody (ANA) testing market has been segmented into immunofluorescence (Primary or direct and Secondary or indirect), enzyme-linked, immunosorbent assay (ELISA) (Direct ELISA, Indirect ELISA, Sandwich ELISA, Competition/Inhibition ELISA), and others.
By application, the Anti-Nuclear Antibody (ANA) testing market has been segmented into Rheumatoid arthritis (Seropositive, Seronegative), Systemic lupus erythematosus (SLE) (Discoid lupus erythematosus, Subacute cutaneous lupus erythematosus, Neonatal lupus), Polymyositis, Scleroderma (localized scleroderma, systemic scleroderma), Sjögren’s syndrome (Primary, secondary), and others.
By end user, the global Anti-Nuclear Antibody (ANA) testing market has been segmented into hospitals and clinics, research laboratories, and others.
Competitive Dashboard:
Some of the key players profiled in the report are Abcam plc. (US), Antibodies Inc.(US), Bio-Rad Laboratories, Inc. (US), Alere (US), Erba Diagnostics (US), MBL International (US), Merck KGaA (Germany), Indur Services, Inc. (US), Trinity Biotech (Republic of Ireland).
Brows Complete Premium Research Report at https://www.marketresearchfuture.com/reports/anti-nuclear-antibody-testing-market-3210
Regional Analysis:
The global Anti-Nuclear Antibody (ANA) testing market, by region, has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is currently holding a dominant share of the global market and is prognosticated to expand significantly during the forecast period. The U.S. FDA has recently approved the new automated diagnostic tests for ANCA-associated vasculitis, which is a form of blood vessel inflammation.
Europe has secured the second largest position in the Anti-Nuclear Antibody (ANA) testing market. It is projected to scale new heights in the upcoming years. The factors that are likely to favor the proliferation of the Anti-Nuclear Antibody (ANA) testing market in the region include increased research & development activities, government support, rising healthcare expenditure, etc.
Asia Pacific resonate strong growth opportunities and is estimated to emerge as the fastest growing Anti-Nuclear Antibody (ANA) testing market in the foreseeable future. The accelerated adoption of novel technologies, evolving healthcare sector, healthy economic growth, growing population, etc. are predicted to catapult the Anti-Nuclear Antibody (ANA) testing market on an upward trajectory.
The Middle East & Africa is expected to account for the least share in the Anti-Nuclear Antibody (ANA) testing market owing to the limited market presence of healthcare devices and treatments. However, the established healthcare sectors of Middle Eastern countries are prognosticated to accrue revenue over the projection period.
Inquire for an Exclusive Discount at https://www.marketresearchfuture.com/check-discount/3210
Innovation and advancements in techniques and technologies are the key areas of focus for the key players. Investments are expected to flow towards the development of more effective and precise tests in the foreseeable future.
This, in turn, is projected to augment the Anti-Nuclear Antibody (ANA) testing market in the upcoming years. For instance, AESKU, an innovation leader in autoimmune diagnostics, has developed new automated diagnostic tests for lupus and ANCA-associated vasculitis, which has been approved by the U.S. Food and Drug Administration (FDA) in June 2018.
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312